|
|
|
|
LEADER |
01637nam a2200289 u 4500 |
001 |
EB001897184 |
003 |
EBX01000000000000001060189 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
200523 r ||| eng |
245 |
0 |
0 |
|a Addendum to NICE guideline 100, alcohol-use disorders
|h Elektronische Ressource
|b diagnosis and management of physical complications
|c developed by the National Institute for Health and Care Excellence
|
246 |
3 |
1 |
|a Alcohol-use disorders
|
260 |
|
|
|a London
|b National Institute for Health and Care Excellence (UK)
|c 2017, April 2017
|
300 |
|
|
|a 1 PDF file (128 pages)
|b illustrations
|
505 |
0 |
|
|a Includes bibliographical references
|
653 |
|
|
|a Alcohol-Related Disorders / complications
|
653 |
|
|
|a United Kingdom
|
653 |
|
|
|a Alcohol-Related Disorders / therapy
|
653 |
|
|
|a Alcohol-Related Disorders / diagnosis
|
710 |
2 |
|
|a National Institute for Health and Care Excellence (Great Britain)
|
740 |
0 |
2 |
|a Alcohol use disorders
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a NICE guideline addendum: methods, evidence, and recommendations
|
856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK550001
|3 Volltext
|
082 |
0 |
|
|a 610
|
520 |
|
|
|a A decision was made to update the NICE guideline on management of alcohol use disorders (CG100) following an exceptional surveillance review of corticosteroid treatment for alcohol-related diseases. Topic experts felt that recent publication of the NIHR-funded STOPAH trial represented significant new evidence that could have an impact on current guideline recommendations
|